IFNA1 and neoplasm: Given the clinical data suggesting type I IFN plays an important role in anti-tumor immunity and response to ICI therapy and the pre-clinical data demonstrating the importance of IFN signaling specifically in the cDC1 DC subset, we developed a cDC1 specific-targeted antibody (Ab) and IFN (Ab-IFN) fusion protein to determine whether systemic administration could induce selective and sustained activation of cDC1s in the tumor and potent anti-tumor activity.